Index of Issues: January–March 1–72; April–June 73–126; July–September 127–180; October–December 181–256.

INDEX OF AUTHORS

A

Alexander ER, 45
Alvarez-Dardet C, 100
Aral SC, 164
Arko RJ, 152
Averous S, 110

B

Baddour LM, 174
Barron AL, 169
Batchelor RA, 196
Bauriaud R, 110
Bech-Thomsen N, 116
Berman S, 200
Berman SM, 51
Berson NL, 63
Bertrand MA, 110
Biddle JW, 196
Blanc C, 110
Bonner M, 45
Boslego JW, 186
Bourgeois AL, 141
Bowie WR, 181
Brayden RM, 200
Brumsted JR, 144
Bucak VA, 174
Burleigh PM, 152

C

Caine V, 11
Camacho F, 100
Carillo C, 73
Casin I, 119
Chernesky MA, 78
Ciak J, 186
Cleavenger RL, 133
Coovadia YM, 30
Craig BT, 152
Cunningham AI, 78

D

Danos CS, 11
D'Costa LJ, 37
DeJong W, 127
Dhamu F, 108
DiPasquale RC, 148
Dolivo M, 119
Ducot B, 119

E

Ehret JM, 156
Elsner P, 150
Embil JA, 5, 85
Escamilla J, 141, 196

F

Faber V, 1
Faro S, 103
Feiten DJ, 200
Fox R, 58
Frazier D, 158

G

Gardiner CH, 141
Gerstoft J, 1
Gibson M, 144
Gili M, 100
Glasner M, 93
Goh BT, 167
Gorrell TE, 17
Greenup R, 186
Grenier-Landis MN, 78
Gutman LT, 63
Gwanzura L, 108

H

Haase D, 85
Hammerschlag MR, 148
Hanuka N, 93
Harrison HR, 51
Hartmann AA, 150
Heaton S, 148
Herman-Giddens ME, 63
Hernández-Aguado I, 100
Hicks CB, 186
Hill LVH, 5
Hoff G, 123
Hofmann B, 1
Hoosen AA, 30
Hrdy DB, 114
Hudson R, 174
Hunter EF, 152

J

Jensen BL, 123
Johnson SR, 217
Jones BM, 35
Jones RB, 11
Jongeling G, 108
Judson FN, 156

K

Kailath EJ, 114
Katz BP, 11
Keeney R, 58
Keenlyside RA, 51
Kent GP, 51
Kharsany A, 30
Khor BS, 25
Kilpatrick ME, 141
Kinghorn GR, 35
Kirshon B, 103
Knapp JS, 158, 202, 225
Koerner EA, 1
Kraus SJ, 192, 234
Kryger P, 1
Kunimoto DY, 37

L

Landis SJ, 78
Lane EW, 196
Laporte A, 119
Lareng MB, 110
Larsen SA, 152
Latif A, 108
Latif AS, 27
Lauer BA, 200
Le Furgy WG, 40
Lefèvre JC, 110
Levendusky P, 58
Lewis JS, 192
Lim KF, 25
Lossick JG, 17
Loveless MO, 73
Luther ER, 5

M

MacNeil JP, 85
Magder L, 164
Mahony JB, 78
Manikowska-Lesinska W, 137
Manley KM, 85
Mantell J, 167
Mapeta D, 108
Marowa E, 108
Mason P, 108
Mason PR, 27
McEvoy BF, 40
Mead PB, 144
Miller M, 73
Morel P, 119
Morse SA, 192, 217
Mostow SR, 73
Mrak RE, 169
Müller M, 17

N

Naaykens W, 181
Namaara W, 37
Ndinya-Achola JO, 37
Neely JL, 133
Ngeow YF, 25
Nielsen CM, 1
Nielsen JO, 1
Nusinoff-Lehrman S, 58

O

O'Connor RP, 73
Oehlenschlager J, 1

P

Palmer JE, 133
Papadimos TJ, 196
Paraiwa E, 27, 108
Pasley JN, 169
Pedersen NS, 1
Perea EJ, 100
Pereira L, 5
Pereira LH, 85
Perol Y, 119
Pessione F, 119
Phillips LE, 103
Plummer FA, 37
Potterat JJ, 88
Proctor EM, 181
Pruett K, 103

Q

Quinn TS, 11

R

Raad II, 73
Rabb JA, 45
Rajakumar MK, 25
Rank RG, 169
Reynolds GH, 234
Rice RJ, 152, 158
Roblin PM, 148
Rolfs RT Jr, 234
Rolland S, 58
Ronald AR, 37
Roongpisuthipong A, 192
Rothenberg R, 211
Rothenberg RB, 88
Ryder LP, 1

S

Sacks SL, 58
Sarov I, 93
Seidelman WE, 78
Sharp KL, 45
Sherertz RJ, 73
Solomon MZ, 127
Somes G, 174
Spira A, 119
Sprechler HH, 1
Stewart IO, 78
Stiver HG, 58
Svejgaard A, 1
Swinker ML, 133

T

Tambo J, 108
Thomas RJ, 186
Thompson SE, 152
Tramont EC, 186

V

van den Berg T, 1
Van Den Ende J, 30
Vanderplate C, 164
Voigt R, 211

W

Walpita P, 167
Weismann K, 123
White HJ, 169
Whittington WL, 158, 202
Wiener HA, 186
Wilson JD, 35
Wong Q, 181
Woodland RM, 167
Wulf HC, 116

Y

Young D, 5
Young SA, 133

Z

Zdrodowska-Stefanow B, 137
Zenilman JM, 45, 158

INDEX OF SUBJECTS

A

Acquired immunodeficiency syndrome, and STD markers and HIV antibodies (Hofmann & others), 1
Acyclovir, chronic suppression for 6 months vs. intermittent lesional therapy with, for genital herpes (Sacks & others), 58
Amoxicillin
  for antimicrobial-resistant gonorrhea, 234
  N. gonorrhoeae susceptibility to (Coovadia & others), 30. *See also* Antimicrobial resistance
Ampicillin
  for antimicrobial-resistant gonorrhea, 234
  N. gonorrhoeae susceptibility to (Coovadia & others), 30. *See also* Antimicrobial resistance
Antibiotics. *See also* Antimicrobial resistance; Antimicrobial susceptibility
  illicit use of, by core group gonorrhea transmitters (Zenilman & others), 45
Antibodies
  C. trachomatis, immunoblotting and immunoperoxidase assays for (Hanuka; Glasner & Sarov), 93
  HIV, and STD markers, and subsequent AIDS (Hofmann & others), 1
Antimicrobial resistance
  of *N. gonorrhoeae*. *See also Neisseria gonorrhoeae*, penicillinase-producing
    and CDC policy guidelines for disease detection, management, and control, 244
    and drug therapy (Kraus; Reynolds & Rolfs), 234
    epidemiologic aspects of (Rothenberg & Voigt), 211
    genetics and mechanisms of (Johnson & Morse), 217
    strain detection and phenotypic characterization in (Knapp), 225
    trends in (Whittington & Knapp), 202
Antimicrobial susceptibility, of *N. gonorrhoeae* (Coovadia & others), 30; (Papadimos & others), 196
Aqueous procaine penicillin G. *See* Penicillin G
Augmentin, *N. gonorrhoeae* susceptibility to (Coovadia & others), 30
Azthreonam, *N. gonorrhoeae* susceptibility to (Coovadia & others), 30

B

Bread-making, and *Saccharomyces cerevisiae* vaginitis (Wilson; Jones & Kinghorn), 35

C

CA-125, and pelvic inflammatory disease (Brumstead; Mead & Gibson), 144
Cefotaxime, vs. cefpimizole, for gonorrhea (Raad & others), 73
Cefoxitin, *N. gonorrhoeae* resistance to (Johnson & Morse), 217; (Knapp), 225
Cefpimizole, vs. cefotazime and penicillin G, for gonorrhea (Raad & others), 73
Ceftriaxone
  for antibiotic-resistant gonorrhea (CDC), 244
  N. gonorrhoeae resistance to (Knapp), 225; (Whittington & Knapp), 202
Centers for Disease Control, policy guidelines of, for detection, management, and control of antibiotic-resistant *N. gonorrhoeae*, 244
Cephalosporins
  N. gonorrhoeae resistance to (Johnson & Morse), 217; (Knapp), 225
  N. gonorrhoeae susceptibility to (Coovadia & others), 30; (Papadimos & others), 196 (CDC), 196;
  for penicillinase-producing *N. gonorrhoeae* (Kraus; Reynolds & Rolfs), 234
Cervicitis
  clinical and epidemiologic vs. microbiologic findings in (Lefèvre & others), 110
  in pregnancy (Hill & others), 5
Chlamydia trachomatis
  enzyme immunoassay vs. cell culture of (Jensen; Hoff & Weismann), 123
  nonoxynol-9 activity against (Ehret & Judson), 156
Chlamydia trachomatis infection
  conjunctival, with simultaneous herpes virus infection (Mantell & others), 167
  field follow-up for (Katz & others), 11
  IgG and IgA antibodies in, immunoblotting and immunoperoxidase assays for (Hanuka; Glasner & Sarov), 93
  in northeastern Poland (Zdrodowska-Stefanow & Manikowska-Lesinska), 137
  and oral contraceptives (Barron & others), 169
  prevalence of, in college gynecology clinic (Swinker & others), 133
  screening for (Kent & others), 51; (Swinker & others), 133
Chlamydia-negative *Ureaplasma*-negative nongonococcal urethritis, and oral sex (Hernández-Aguado & others), 100
Chlamydial pneumonia of infancy, in siblings (Brayden & others), 200
Cigarette smoking, and urethritis (Pessione & others), 119
Condylomata accuminata, and coexisting vaginal infections, in female children abused by multiple abusers (Herman-Giddens & others), 63
Conjunctiva, dual herpes simplex virus and *C. trachomatis* infection of (Mantell & others), 167
Core group transmission
  of gonorrhea (Rothenberg & Potterat), 88
    and illicit antibiotic use (Zenilman & others), 45
Culdocentesis, vs. ultrasonography, in pelvic inflammatory disease diagnosis, and disease severity (Kirshon & others), 103
Cytomegalovirus seropositivity, in homosexual vs. heterosexual men (Embil & others), 85

D

Dade County, Florida. *See* Miami
Donovanosis, treatment of (Latif; Mason & Paraiwai), 27
Doxycycline
  for antibiotic-resistant gonorrhea (CDC), 244
  vs. ofloxacin, for uncomplicated male urethritis (Boslego & others), 186

E

Educational videotape, clinic-based, for gonorrhea (Solomon & DeJong), 127
Enzyme immunoassay
  for gonococcal urethritis (Roongpisuthipong & others), 192
  vs. cell culture, of *C. trachomatis* (Jensen; Hoff & others), 123
Erythromycin, for antibiotic-resistant gonorrhea (CDC), 244; (Kraus; Reynolds & Rolfs), 234

F

Fellatio
  and *Chlamydia*-negative *Ureaplasma*-negative nongonococcal urethritis (Hernández-Aguado & others), 100
  and *N. meningitidis* Group B urethritis (Hartmann & Elsner), 150
Florida. *See* Miami
Fluoridated quinolones. *See* Quinolones
Force of infectivity, and gonorrhea transmission (Rothenberg & Potterat), 88

G

Genital herpes
recurrent, psychosocial adjustment to, 164
six-month suppression vs. intermittent lesional therapy for, with acyclovir (Sacks & others), 58
Genital tract infections
lower
microbiology of, vs. clinical and epidemiologic findings (Lefevre & others), 110
prevalence of, in pregnancy (Hill & others), 5
Genital warts, and coexisting vaginal infections, in female children abused by multiple abusers (Herman-Giddens & others), 63
Gonococcal ophthalmia neonatorum, kanamycin and saline irrigation for (Latif & others), 108
Gonorrhea. *See also Neisseria gonorrhoeae;* Urethritis
antimicrobial-resistant
treatment of (Kraus; Reynolds & Rolfs), 234
CDC policy guidelines for detection, management, and control of, 244
cefpimizole vs. cefotazime and penicillin G for (Raad & others), 73
clinic-based educational videotape for (Solomon & DeJong), 127
core group transmission of (Rothenberg & Potterat), 88
illicit antibiotic use by (Zenilman & others), 45
ofloxacin for (Rajakumar & others), 25
pharyngeal, trimethoprim-sulfamethoxazole for (Wulf & Bech-Thomsen), 116
recurrent, risk factor and clinic visitation pattern analysis for (McEvoy & Furgy), 40
transmission of
core group (Rothenberg & Potterat), 88; (Zenilman & others), 45
and force of infectivity (Rothenberg & Potterat), 88
temporal and social aspects of (Rothenberg & Potterat), 88
Gram-stained urethral smear, for urethritis (Landis & others), 78
Granuloma inguinale, treatment of (Latif; Mason & Paraiwa), 27
Group self-selection, and gonorrhea transmission (Rothenberg & Potterat), 88

H

Haemophilus ducreyi urethritis, in men (Kunimoto & others), 37
Hematoma, *M. hominis* infection of (Kailath & Hrdy), 114
Hepatitis A and B markers, HIV antibodies, and subsequent AIDS (Hofmann & others), 1
Hepatitis B virus infection, risk factors for (Baddour & others), 175
Herpes simplex virus infection
conjunctival, with simultaneous *C. trachomatis* infection (Mantell & others), 167
genital, six-month suppression vs. intermittent lesional therapy for, with acyclovir (Sacks & others), 58
recurrent, psychosocial adjustment to (Aral; Vanderplate & Magder), 164
Homosexual men
Chlamydia-negative *Ureaplasma*-negative nongonococcal urethritis in, and oral sex (Hernández-Aguado & others), 100
cytomegalovirus seropositivity in (Embil & others), 85
STD markers and HIV antibodies in, and subsequent AIDS (Hofmann & others), 1
Human immunodeficiency virus antibodies, STD markers, and subsequent AIDS (Hofmann & others), 1

I

IgA and IgG antibodies, *C. trachomatis,* immunoblotting and immunoperoxidase assays for (Hanuka; Glasner & Sarov), 93
Imipenem, *N. gonorrhoeae* susceptibility to (Coovadia & others), 30
Immunoblotting assay, for *C. trachomatis* antibodies (Hanuka; Glasner & Sarov), 93
Immunoperoxidase assay, for *C. trachomatis* antibodies (Hanuka; Glasner & Sarov), 93

K

Kanamycin
for antibiotic-resistant gonorrhea (Kraus; Reynolds & Rolfs), 234
for gonococcal ophthalmia neonatorum (Latif & others), 108

L

β-Lactam antibiotics, *N. gonorrhoeae* susceptibility to (Coovadia & others), 30
Latin American seaport cities, penicillinase-producing *N. gonorrhoeae* in (Escamilla & others), 141
Lymphogranuloma venereum, in pregnancy (Heaton & others), 148

M

Metronidazole, *T. vaginalis* susceptibility to (Muller; Lossick & Gorrell), 17
Miami
isolates of penicillinase-producing *N. gonorrhoeae* from, core-group transmitters of, and illicit antibiotic use (Zenilman & others), 45
phenotypic characterization of (Zenilman & others), 158
Mycoplasma hominis infection, of hematoma (Kailath & Hrdy), 114

N

Neisseria gonorrhoeae
antimicrobial resistance of
and CDC policy guidelines for disease detection, management, and control, 244
drug therapy for (Kraus; Reynolds & Rolfs), 234
epidemiology of (Rothenberg & Voigt), 211
genetics and mechanisms of (Johnson & Morse), 217
strain detection and phenotypic characterization in (Knapp), 225
trends in (Whittington & Knapp), 202
penicillinase-producing
control of, epidemiologic aspects of (Rothenberg & Voigt), 211
core group transmitters of, illicit antibiotic use by (Zenilman & others), 45
isolates of from Dade County, Florida, phenotypic characterization of (Zenilman & others), 158
in Latin American seaport cities (Escamilla & others), 141
antimicrobial susceptibility of (Coovadia & others), 30; (Papdimos & others), 196
Neisseria meningitidis group B urethritis (Hartmann & Elsner), 150
Nonoxynol-9, activity of against *C. trachomatis* (Ehret & Judson), 156
Norfloxacin, for antibiotic-resistant gonorrhea (Kraus; Reynolds & Rolfs), 234

O

Ofloxacin
vs. doxycycline, for uncomplicated male urethritis (Boslego & others), 186
for gonorrhea (Rajakumar & others), 25
Ophthalmia neonatorum, gonococcal, kanamycin and saline irrigation for (Latif & others), 108
Oral contraceptives, and *C. trachomatis* salpingitis (Barron & others), 169
Oral sex
and *Chlamydia*-negative *Ureaplasma*-negative nongonococcal urethritis, 100
and *N. meningitidis* Group B urethritis (Hartmann & Elsner), 150

P

Pelvic inflammatory disease
and oral contraceptives (Barron & others), 169

serum CA-125 in (Brumstead; Mead & Gibson), 144
severity of, and diagnosis by culdocentesis vs. ultrasonography (Kirshon & others), 103
Penicillin
N. gonorrhoeae resistance to (Johnson & Morse), 217; (Knapp), 225; (Whittington & Knapp), 202. *See also Neisseria gonorrhoeae,* penicillinase-producing
detection and phenotypic characterization in (Knapp), 217
genetics and mechanisms of (Johnson & Morse) characterization in (Knapp), 217
Penicillin G
for antibiotic-resistant gonorrhea (Kraus; Reynolds & Rolfs), 234
vs. cefpimizole, for gonorrhea (Raad & others), 73
N. gonorrhoeae susceptibility to (Coovadia & others), 30
Pharnygeal gonorrhea, trimethoprim-sulfamethoxazole for (Wulf & Bech-Thomsen), 116
Pneumonia, chlamydial, of infancy, in siblings (Brayden & others), 200
Poland, *C. trachomatis* infection in (Zdrodowska-Stefanow & Manikowska-Lesinska), 137
Pregnancy
lower genital tract infections in, prevalence of (Hill & others), 5
lymphogranuloma venereum in (Heaton & others), 148
Protein CA-125, and pelvic inflammatory disease (Brumstead; Mead & Gibson), 144

Q

Quinolones
N. gonorrhoeae resistance to, genetics and mechanisms of (Johnson & Morse), 217
for uncomplicated male urethritis (Boslego & others), 186

R

Rifampicin, for antibiotic-resistant gonorrhea (Kraus; Reynolds & Rolfs), 234

S

Saccharomyces cerevisiae vaginitis, and bread-making (Wilson; Jones & Kinghorn), 35
Serum CA-125, and pelvic inflammatory disease (Brumstead; Mead & Gibson), 144
Sexual abuse, by multiple abusers, and genital warts and coexisting vaginal infections, in female children (Herman-Giddens & others), 63
Sexually transmitted disease markers, HIV antibodies, and subsequent AIDS (Hofmann & others), 1
Smoking, and urethritis (Pessione & others), 119
Spectinomycin, *N. gonorrhoeae* resistance to (Knapp), 225; (Whittington & Knapp), 202
Sulfamethoxazole. *See* Trimethoprim-sulfamethoxazole
Sulfonamides, *N. gonorrhoeae* resistance to, genetics and mechanisms of (Johnson & Morse), 217
Syphilis
markers of, HIV antibodies, and subsequent AIDS (Hofmann & others), 1
tropectomycin for (Rice & others), 152

T

Temocillin, *N. gonorrhoeae* susceptibility to (Coovadia & others), 30
Tetracycline
for antibiotic-resistant gonorrhea (CDC), 244
N. gonorrhoeae resistance to (Whittington & Knapp), 202
detection and phenotypic characterization in (Knapp), 225
genetics and mechanisms of (Johnson & Morse), 217
Treponema pallidum, response of to trospectomycin (Rice & others), 152
Trichomonas vaginalis
isoenzyme patterns of (Proctor & others), 181
susceptibility of, to metronidazole (Muller; Lossick & Gorrell), 17
Trimethoprim-sulfamethoxazole
N. gonorrhoeae resistance to, genetics and mechanisms of (Johnson & Morse), 217
for pharyngeal gonorrhea (Wulf & Bech-Thomsen), 116
Trospectomycin, tissue fluid penetration and anti-treponemal activity of (Rice & others), 152

U

Ultrasonography, vs. culdocentesis, in pelvic inflammatory disease diagnosis, and disease severity, 103
Urethral smear, gram-stained, for urethritis (Landis & others), 78
Urethritis. *See also* Gonorrhea
diagnosis of
enzyme immunoassay for (Roongpisuthipong & others), 192
gram-stained urethral smear for (Landis & others), 78
H. ducreyi (Kunimoto & others), 37
N. meningitidis group B (Hartmann & Elsner), 150
nongonococcal, *Chlamydia*-negative *Ureaplasma*-negative, and oral sex (Hernández-Aguado & others), 100
ofloxacin vs. doxycycline for (Boslego & others), 186
and smoking (Pessione & others), 119

V

Vaginal infections, with genital warts, and multiple abusers, in female children (Herman-Giddens & others), 63
Vaginitis
clinical and epidemiologic vs. microbiologic findings in (Lefèvre & others), 110
prevalence of, in pregnancy (Hill & others), 5
Saccharomyces cerevisiae, and bread-making (Wilson; Jones & Kinghorn), 35
trichomonial, treatment outcome in, and metronidazole susceptibility (Muller; Lossick & Gorrell), 17
Venereal warts, and coexisting vaginal infections, in female children abused by multiple abusers Herman-Giddens & others), 63
Verruca vulgaris, and coexisting vaginal infections, in female children abused by multiple abusers (Herman-Giddens & others), 63
Videotape, clinic-based educational, for gonorrhea (Solomon & DeJong), 127
Vulvitis, clinical and epidemiologic vs. microbiologic findings in Lefèvre & others), 110

W

Warts, venereal, and coexisting vaginal infections, in female children abused by multiple abusers (Herman-Giddens & others), 63

Y

Yeast, for bread-making, and *Saccharomyces cerevisiae* vaginitis (Wilson; Jones & Kinghorn), 35